Literature DB >> 11514835

von Willebrand factor antigen levels in plasma of patients with malignant breast disease.

L M Röhsig1, D C Damin, S D Stefani, C G Castro, I Roisenberg, G Schwartsmann.   

Abstract

von Willebrand factor (vWF) is a protein that mediates platelet adherence to the subendothelium during primary hemostasis. High plasma vWF concentrations have been reported in patients with various types of cancer, such as head and neck, laryngeal and prostatic cancer, probably representing an acute phase reactant. In the present study we determined the plasma levels of vWF antigen (vWF:Ag) by quantitative immunoelectrophoresis in 128 female patients with breast cancer as well as in 47 women with benign breast disease and in 27 healthy female controls. The levels of vWF:Ag were 170.7 +/- 78 U/dl in patients with cancer, 148.4 +/- 59 U/dl in patients with benign disease and 130.6 +/- 45 U/dl in controls (P<0.005). We also detected a significant increase in the levels of vWF:Ag (P<0.0001) in patients with advanced stages of the disease (stage IV = 263.3 +/- 113 U/dl, stage IIIB = 194.0 +/- 44 U/dl) as compared to those with earlier stages of the disease (stage I = 155.3 +/- 65 U/dl, stage IIA = 146.9 +/- 75 U/dl). In conclusion, vWF levels were increased in plasma of patients with malignant breast disease, and these levels correlated with tumor progression.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11514835     DOI: 10.1590/s0100-879x2001000900004

Source DB:  PubMed          Journal:  Braz J Med Biol Res        ISSN: 0100-879X            Impact factor:   2.590


  10 in total

Review 1.  Role of von Willebrand factor levels in the prognosis of stage IV colorectal cancer: do we have enough evidence?

Authors:  I Gil-Bazo; J-A Díaz-González; J Rodríguez; J Cortés; E Calvo; J-A Páramo; J García-Foncillas
Journal:  World J Gastroenterol       Date:  2005-10-14       Impact factor: 5.742

2.  Glioblastoma and ABO blood groups: further evidence of an association between the distribution of blood group antigens and brain tumours.

Authors:  Mohammed Z Allouh; Mohammed M Al Barbarawi; Mohammad Y Hiasat; Mohammed A Al-Qaralleh; Emad I Ababneh
Journal:  Blood Transfus       Date:  2016-06-30       Impact factor: 3.443

3.  Increased von Willebrand factor over decreased ADAMTS-13 activity is associated with poor prognosis in patients with advanced non-small-cell lung cancer.

Authors:  Renyong Guo; Jiezuan Yang; Xia Liu; Jianping Wu; Yu Chen
Journal:  J Clin Lab Anal       Date:  2017-04-04       Impact factor: 2.352

4.  Hyperglycemia-induced oxidative stress promotes tumor metastasis by upregulating vWF expression in endothelial cells through the transcription factor GATA1.

Authors:  Han-Seok Jeong; Da-Hye Lee; Seung-Hoon Kim; Chang-Han Lee; Hyun Mu Shin; Hang-Rae Kim; Chung-Hyun Cho
Journal:  Oncogene       Date:  2022-01-29       Impact factor: 8.756

Review 5.  A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity.

Authors:  Anne Polk; Kirsten Vistisen; Merete Vaage-Nilsen; Dorte L Nielsen
Journal:  BMC Pharmacol Toxicol       Date:  2014-09-04       Impact factor: 2.483

6.  Prognostic value of preoperative von Willebrand factor plasma levels in patients with Glioblastoma.

Authors:  Giovanni Marfia; Stefania Elena Navone; Claudia Fanizzi; Silvia Tabano; Chiara Pesenti; Loubna Abdel Hadi; Andrea Franzini; Manuela Caroli; Monica Miozzo; Laura Riboni; Paolo Rampini; Rolando Campanella
Journal:  Cancer Med       Date:  2016-05-28       Impact factor: 4.452

7.  The role of ADAMTS-13 and von Willebrand factor in cancer patients: Results from the Vienna Cancer and Thrombosis Study.

Authors:  Hanna L Obermeier; Julia Riedl; Cihan Ay; Silvia Koder; Peter Quehenberger; Rupert Bartsch; Alexandra Kaider; Christoph C Zielinski; Ingrid Pabinger
Journal:  Res Pract Thromb Haemost       Date:  2019-05-06

Review 8.  The role of VWF/FVIII in thrombosis and cancer progression in multiple myeloma and other hematological malignancies.

Authors:  Claire Comerford; Siobhan Glavey; John Quinn; Jamie M O'Sullivan
Journal:  J Thromb Haemost       Date:  2022-06-23       Impact factor: 16.036

9.  A list of candidate cancer biomarkers for targeted proteomics.

Authors:  Malu Polanski; N Leigh Anderson
Journal:  Biomark Insights       Date:  2007-02-07

10.  Time-dependent interactions of blood platelets and cancer cells, accompanied by extramedullary hematopoiesis, lead to increased platelet activation and reactivity in a mouse orthotopic model of breast cancer - implications for pulmonary and liver metastasis.

Authors:  Hassan Kassassir; Kamil Karolczak; Karolina M Siewiera; Dagmara W Wojkowska; Marcin Braun; Cezary W Watala
Journal:  Aging (Albany NY)       Date:  2020-03-19       Impact factor: 5.682

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.